Amicus Therapeutics
FOLD
Market cap $2.93B

9.79 USD

-0.05

0.51%

At close Dec 24, 4:00 PM EST

1 day

-0.51%

5 days

-0.81%

1 month

0.72%

3 months

-12.75%

6 months

-2.10%

Year to date

-31.25%

1 year

-30.52%

5 years

-4.67%

10 years

23.30%

About: Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Employees: 517

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

115% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 27

20% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]

12% more funds holding

Funds holding: 255 [Q2] → 286 (+31) [Q3]

3% more capital invested

Capital invested by funds: $3.17B [Q2] → $3.28B (+$102M) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 91

4.59% less ownership

Funds ownership: 108.04% [Q2] → 103.45% (-4.59%) [Q3]

29% less call options, than puts

Call options by funds: $6.37M | Put options by funds: $8.9M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

23%

upside

Avg. target

$16.83

72%

upside

High target

$21

115%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Morgan Stanley Jeffrey Hung 35% 1-year accuracy 6 / 17 met price target	23%upside $12	Equal-Weight Downgraded	13 Dec 2024
JP Morgan Anupam Rama 25% 1-year accuracy 15 / 59 met price target	74%upside $17	Overweight Maintained	12 Nov 2024
Guggenheim Debjit Chattopadhyay 40% 1-year accuracy 8 / 20 met price target	53%upside $15	Buy Maintained	7 Nov 2024
UBS Karl Chalabala 50% 1-year accuracy 1 / 2 met price target	115%upside $21	Buy Maintained	7 Nov 2024
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target	115%upside $21	Overweight Maintained	7 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about FOLD published over the past 30 days

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Zacks Investment Research

HALO or FOLD: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?

HALO or FOLD: Which Is the Better Value Stock Right Now?

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al.

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Zacks Investment Research

Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Zacks Investment Research

HALO vs. FOLD: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors?

HALO vs. FOLD: Which Stock Is the Better Value Option?

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

Zacks Investment Research

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

See News Rankings

Charts implemented using Lightweight Charts™